Delix Therapeutics
The best way to predict the future is to invent it.
Dr. Meyer is a neuroscientist by training and an entrepreneur by profession. Her mission is to galvanize the era of precision medicine for brain health. To that end, she has been founder, advisor, or early employee in several startups and biotechs working to develop or support objective diagnostics or personalized therapeutics for neurology.
At Delix Therapeutics, Dr. Meyer’s role is Head of Corporate Strategy. Our team at Delix supports efforts across all verticals to achieve their major aims. We remove obstacles.
Before Delix, Dr. Meyer worked as an EIR for hire working with VCs, Startups, and Academic Entrepreneurs as a trusted scientific advisor, strategy consultant, and transitional leader to translate visionary science to commercial endeavors.
She serves on the Board of the Museum of Science, Boston, and the Advisory Boards for PYM, Inc and Concerto Bio. She has her PhD in Neuroscience and Neuroendocrinology from MIT, was a Fulbright Fellow at NTNU in the Moser lab, and graduated University of Arizona with degrees in Mathematics, Biochemistry & Molecular Biophysics, and Biopsychology.
This person is not in any offices
Delix Therapeutics
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.